Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia

Catharina Müller-Thomas, Martina Rudelius, Ina Christine Rondak, Torsten Haferlach, Julie Schanz, Christina Huberle, Burkhard Schmidt, Rainer Blaser, Marcus Kremer, Christian Peschel, Ulrich Germing, Uwe Platzbecker, Katharina Götze

Research output: Contribution to journalLetterpeer-review

54 Scopus citations
Original languageEnglish
Pages (from-to)e179-e181
JournalHaematologica
Volume99
Issue number10
DOIs
StatePublished - 1 Oct 2014

Keywords

  • Azacitidine
  • MDS
  • TP53 mutations
  • p53 expression

Cite this